192 related articles for article (PubMed ID: 24863690)
1. Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib.
Vergote V; Dierickx D; Janssens A; Verhoef G; Tousseyn T; Vandenberghe P; Wolter P; Delforge M
Ann Hematol; 2014 Dec; 93(12):2087-9. PubMed ID: 24863690
[No Abstract] [Full Text] [Related]
2. Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis.
Maurer H; Haas P; Wengenmayer T; Lübbert M; Duyster J; Zeiser R
Ann Hematol; 2014 Aug; 93(8):1439-40. PubMed ID: 24337488
[No Abstract] [Full Text] [Related]
3. Complete Cytologic Remission of V600E BRAF-Mutant Melanoma-Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib.
Wilgenhof S; Neyns B
J Clin Oncol; 2015 Oct; 33(28):e109-11. PubMed ID: 24733801
[No Abstract] [Full Text] [Related]
4. BRAF inhibitor therapy in HCL.
Dietrich S; Zenz T
Best Pract Res Clin Haematol; 2015 Dec; 28(4):246-52. PubMed ID: 26614903
[TBL] [Abstract][Full Text] [Related]
5. Hairy cell leukemia: update and current therapeutic approach.
Salam L; Abdel-Wahab O
Curr Opin Hematol; 2015 Jul; 22(4):355-61. PubMed ID: 26049757
[TBL] [Abstract][Full Text] [Related]
6. Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.
Blachly JS; Lozanski G; Lucas DM; Grever MR; Kendra K; Andritsos LA
J Natl Compr Canc Netw; 2015 Jan; 13(1):9-13; quiz 13. PubMed ID: 25583765
[TBL] [Abstract][Full Text] [Related]
7. Dramatic transient improvement of metastatic BRAF(V600E)-mutated Langerhans cell sarcoma under treatment with dabrafenib.
Mourah S; Lorillon G; Meignin V; Vercellino L; de Margerie-Mellon C; Pages C; Goldwirt L; How-Kit A; Tost J; Lebbe C; Tazi A
Blood; 2015 Dec; 126(24):2649-52. PubMed ID: 26468227
[No Abstract] [Full Text] [Related]
8. Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases.
Palomera L; Domingo JM; Sola C; Azaceta G; Calvo MT; Gutierrez M
Haematologica; 2002 Jan; 87(1):107-8. PubMed ID: 11801472
[No Abstract] [Full Text] [Related]
9. Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment.
Fietz T; Rieger K; Schmittel A; Thiel E; Knauf W
Hematol J; 2004; 5(5):451-2. PubMed ID: 15448675
[No Abstract] [Full Text] [Related]
10. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia.
Dietrich S; Hüllein J; Hundemer M; Lehners N; Jethwa A; Capper D; Acker T; Garvalov BK; Andrulis M; Blume C; Schulte C; Mandel T; Meissner J; Fröhling S; von Kalle C; Glimm H; Ho AD; Zenz T
J Clin Oncol; 2013 Jul; 31(19):e300-3. PubMed ID: 23690412
[No Abstract] [Full Text] [Related]
11. BRAF inhibitor activity in V600R metastatic melanoma.
Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
[TBL] [Abstract][Full Text] [Related]
12. Hairy cell leukemia.
Dearden C
Best Pract Res Clin Haematol; 2015 Dec; 28(4):163-5. PubMed ID: 26614893
[No Abstract] [Full Text] [Related]
13. Treatment of patients with hairy cell leukemia with 2-chloro-2'-deoxyadenosine (2-CdA).
Robak T; Krykowski E; Błasińska-Morawiec M; Urbańska-Ryś H
Arch Immunol Ther Exp (Warsz); 1994; 42(1):25-9. PubMed ID: 7503629
[TBL] [Abstract][Full Text] [Related]
14. Hairy cell leukemia: Past, present and future.
Getta BM; Park JH; Tallman MS
Best Pract Res Clin Haematol; 2015 Dec; 28(4):269-72. PubMed ID: 26614906
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial.
Tiacci E; De Carolis L; Simonetti E; Merluzzi M; Bennati A; Perriello VM; Pucciarini A; Santi A; Venanzi A; Pettirossi V; Schiavoni G; Tasselli L; Ascani S; Volpetti S; Falini B
Leukemia; 2021 Nov; 35(11):3314-3318. PubMed ID: 33731847
[No Abstract] [Full Text] [Related]
16. Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment.
Maitre E; Cornet E; Troussard X
Am J Hematol; 2019 Dec; 94(12):1413-1422. PubMed ID: 31591741
[TBL] [Abstract][Full Text] [Related]
17. [Dabrafenib: the new inhibitor of hyperactive B-RAF kinase].
Heneberg P
Klin Onkol; 2012; 25(5):333-9. PubMed ID: 23102194
[TBL] [Abstract][Full Text] [Related]
18. Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia.
Jones JA; Kraut EH; Deam D; Byrd JC; Grever MR
Leuk Lymphoma; 2012 Mar; 53(3):490-1. PubMed ID: 22165992
[No Abstract] [Full Text] [Related]
19. BRAF(V600E) mutation in a histiocytic sarcoma arising from hairy cell leukemia.
Michonneau D; Kaltenbach S; Derrieux C; Trinquand A; Brouzes C; Gibault L; North MO; Delarue R; Varet B; Emile JF; Brousse N; Hermine O
J Clin Oncol; 2014 Dec; 32(35):e117-21. PubMed ID: 24567436
[No Abstract] [Full Text] [Related]
20. Historical overview of hairy cell leukemia.
Andritsos LA; Grever MR
Best Pract Res Clin Haematol; 2015 Dec; 28(4):166-74. PubMed ID: 26614894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
